GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioGaia AB (LTS:0GTN) » Definitions » EV-to-EBIT

BioGaia AB (LTS:0GTN) EV-to-EBIT : 21.76 (As of Apr. 30, 2024)


View and export this data going back to 2013. Start your Free Trial

What is BioGaia AB EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, BioGaia AB's Enterprise Value is kr10,220 Mil. BioGaia AB's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was kr470 Mil. Therefore, BioGaia AB's EV-to-EBIT for today is 21.76.

The historical rank and industry rank for BioGaia AB's EV-to-EBIT or its related term are showing as below:

LTS:0GTN' s EV-to-EBIT Range Over the Past 10 Years
Min: 12.99   Med: 27.33   Max: 52.19
Current: 21.76

During the past 13 years, the highest EV-to-EBIT of BioGaia AB was 52.19. The lowest was 12.99. And the median was 27.33.

LTS:0GTN's EV-to-EBIT is ranked worse than
60.33% of 668 companies
in the Drug Manufacturers industry
Industry Median: 17.14 vs LTS:0GTN: 21.76

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. BioGaia AB's Enterprise Value for the quarter that ended in Dec. 2023 was kr8,652 Mil. BioGaia AB's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was kr470 Mil. BioGaia AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 5.43%.


BioGaia AB EV-to-EBIT Historical Data

The historical data trend for BioGaia AB's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioGaia AB EV-to-EBIT Chart

BioGaia AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.43 41.12 35.41 15.34 18.47

BioGaia AB Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.34 15.21 20.50 16.27 18.47

Competitive Comparison of BioGaia AB's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioGaia AB's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where BioGaia AB's EV-to-EBIT falls into.



BioGaia AB EV-to-EBIT Calculation

BioGaia AB's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=10220.247/469.643
=21.76

BioGaia AB's current Enterprise Value is kr10,220 Mil.
BioGaia AB's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr470 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioGaia AB  (LTS:0GTN) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

BioGaia AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=469.643/8652.164504
=5.43 %

BioGaia AB's Enterprise Value for the quarter that ended in Dec. 2023 was kr8,652 Mil.
BioGaia AB's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr470 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioGaia AB EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of BioGaia AB's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


BioGaia AB (LTS:0GTN) Business Description

Traded in Other Exchanges
Address
Kungsbroplan 3A, Stockholm, SWE, SE-112 27
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions; Asia Pacific, Europe, the Middle East, Africa, and the Americas.

BioGaia AB (LTS:0GTN) Headlines

No Headlines